| Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial.Acta Derm Venereol | PMID 38436429PMC10924269 | 2024-Mar-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate.JAMA Netw Open | PMID 38488793PMC10943414 | 2024-Mar-04 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 38387470无 PMCID | 2024-Mar-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis.Int Clin Psychopharmacol | PMID 37551609PMC10833186 | 2024-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.Am J Gastroenterol | PMID 37561058PMC10903997 | 2024-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.Haematologica | PMID 37646660PMC10905085 | 2024-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-Term Results From the PKUFH Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys | PMID 37717784无 PMCID | 2024-Mar-01 | 0.85 | The study is an eligible Phase III randomized oncology trial with time-to-event endpoints, but the intervention is radiation therapy alone, not a drug-containing intervention as required by the adjudication criteria. | 待处理 |
| Racecadotril Versus Loperamide in Acute Radiation Enteritis: A Randomized, Double-Masked, Phase 3, Noninferiority Trial.Int J Radiat Oncol Biol Phys | PMID 37742773无 PMCID | 2024-Mar-01 | 0.95 | The trial meets criteria for being a human, oncology-context, Phase III randomized trial with a drug intervention and is an original result. However, it is excluded because the primary efficacy endpoint is not a time-to-event endpoint (e.g., OS, PFS, DFS) or a Kaplan-Meier/HR analysis; it is a categorical response rate at a fixed time point. | 待处理 |
| Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.J Crohns Colitis | PMID 37797293PMC10906949 | 2024-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.J Clin Oncol | PMID 38042525PMC10906563 | 2024-Mar-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.J Travel Med | PMID 38091981PMC10911060 | 2024-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 38127362PMC10739077 | 2024-Mar-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.J Clin Oncol | PMID 38194625PMC10906638 | 2024-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 38236590PMC10797521 | 2024-Mar-01 | 0.95 | The trial is ineligible because it lacks a primary or key secondary time-to-event efficacy endpoint. All specified criteria for inclusion require a TTE endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier analysis, which are absent from this report. | 待处理 |
| VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.J Am Soc Nephrol | PMID 38261535PMC10914188 | 2024-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.JAMA Pediatr | PMID 38315470PMC10845038 | 2024-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel.J Drugs Dermatol | PMID 38443130无 PMCID | 2024-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing Impact of Overactive Bladder Therapies on Nocturia.Urogynecology (Phila) | PMID 38484241无 PMCID | 2024-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.Eur Urol | PMID 37778952无 PMCID | 2024-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The Orphan Drug for Acanthamoeba Keratitis (ODAK) Trial: PHMB 0.08% (Polihexanide) and Placebo versus PHMB 0.02% and Propamidine 0.1.Ophthalmology | PMID 37802392无 PMCID | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| START NOW: a cognitive behavioral skills training for adolescent girls with conduct or oppositional defiant disorder - a randomized clinical trial.J Child Psychol Psychiatry | PMID 37814906无 PMCID | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.J Am Acad Dermatol | PMID 37852306无 PMCID | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.Lancet Infect Dis | PMID 38008099无 PMCID | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.Clin Pharmacol Ther | PMID 38012534无 PMCID | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.Ann Oncol | PMID 38048850无 PMCID | 2024-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.Leukemia | PMID 38062124PMC10912032 | 2024-Mar | 0.45 | The study is a secondary analysis of pooled Phase III trials in multiple myeloma, focusing on morbidity and mortality during induction therapy. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or hazard ratio data. | 待处理 |
| A Randomized Phase III Trial of Complete Mesocolic Excision Compared with Conventional Surgery for Right Colon Cancer: Interim Analysis of a Nationwide Multicenter Study of the Italian Society of Surgical Oncology Colorectal Cancer Network (CoME-in trial).Ann Surg Oncol | PMID 38087139PMC10838239 | 2024-Mar | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.Lancet Infect Dis | PMID 38109921PMC10881405 | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.J Allergy Clin Immunol Pract | PMID 38122865无 PMCID | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacotherapy for the Prevention of Depression and Behavioral Side Effects in Hematopoietic Stem Cell Transplantation Patients.Transplant Cell Ther | PMID 38147899无 PMCID | 2024-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.Adv Ther | PMID 38183525PMC10879225 | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Co-crystal of Tramadol-Celecoxib Versus Tramadol or Placebo for Acute Moderate-to-Severe Pain After Oral Surgery: Randomized, Double-Blind, Phase 3 Trial (STARDOM1).Adv Ther | PMID 38183526PMC10879371 | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.Adv Ther | PMID 38194047PMC10879230 | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.Lancet Gastroenterol Hepatol | PMID 38211604无 PMCID | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.Paediatr Drugs | PMID 38267692PMC10890978 | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study.Respir Investig | PMID 38277865无 PMCID | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.Gastric Cancer | PMID 38281295PMC10896803 | 2024-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.Clin Drug Investig | PMID 38300386无 PMCID | 2024-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study.Nat Med | PMID 38302715无 PMCID | 2024-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.Eur J Cancer | PMID 38309017无 PMCID | 2024-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial.J Clin Hypertens (Greenwich) | PMID 38319595PMC10918710 | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.Lancet Diabetes Endocrinol | PMID 38330988无 PMCID | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.Lung Cancer | PMID 38354535无 PMCID | 2024-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Anxiety-focused cognitive behavioral therapy delivered by non-specialists to prevent postnatal depression: a randomized, phase 3 trial.Nat Med | PMID 38365951PMC11060845 | 2024-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.Lancet Haematol | PMID 38423700无 PMCID | 2024-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.Target Oncol | PMID 38427280PMC10963434 | 2024-Mar | 0.90 | The record describes a single-arm Phase II trial. While it is an oncology study on human patients and reports a time-to-event outcome (PFS), it is excluded because it is not a randomized controlled trial and is only a Phase II study, not a Phase III or otherwise definitive randomized trial as required. | 待处理 |
| Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.Lancet Healthy Longev | PMID 38432247无 PMCID | 2024-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial.ESMO Open | PMID 38471240PMC10944099 | 2024-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| The feasibility and acceptability of an app-based intervention with brief behavioural support (APPROACH) to promote brisk walking in people diagnosed with breast, prostate and colorectal cancer in the UK.Cancer Med | PMID 38529687PMC10964176 | 2024-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.N Engl J Med | PMID 37962077无 PMCID | 2024-Feb-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |